What is Evelo Biosciences Operating Cash Flow per Share?
Evelo Biosciences's operating cash flow per share for the
three
months ended in Sep. 2023 was $-1.20.
Evelo Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.62.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 19.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Evelo Biosciences's Operating Cash Flow per Share or its related term are showing as below:
EVLO'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 5.4 Med: 15.75 Max: 33.1
Current: 19.7
During the past 7 years, Evelo Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 33.10% per year. The lowest was 5.40% per year. And the median was 15.75% per year.
EVLO's 3-Year OCF Growth Rate is ranked better than 68.15% of 1240
companies
in the Biotechnology industry
Industry Median: 3.55
vs EVLO: 19.70
Evelo Biosciences Operating Cash Flow per Share Historical Data
The historical data trend for Evelo Biosciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Evelo Biosciences Operating Cash Flow per Share Chart
Competitive Comparison of Evelo Biosciences's Operating Cash Flow per Share
For the Biotechnology subindustry, Evelo Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evelo Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Evelo Biosciences's Price-to-Operating-Cash-Flow falls into.
Evelo Biosciences Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Evelo Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evelo Biosciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Evelo Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Evelo Biosciences (Evelo Biosciences) Business Description
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVLO has been successfully added to your 